|
Patent landscape, scope, and claims summary: |
United States Patent 9,273,132: Analysis of Claims and Landscape
What is the Core Innovation of US Patent 9,273,132?
United States Patent 9,273,132, titled "Combination therapies for treating cancer," was granted to Merck Sharp & Dohme Corp. on March 1, 2016. The patent covers specific combination treatments for various types of cancer, primarily focusing on the synergistic effect of combining an anti-PD-1 antibody with an anti-CTLA-4 antibody. The claimed compounds are designed to enhance the immune response against tumor cells by targeting two distinct immune checkpoints.
The patent’s independent claims define methods of treating cancer by administering a combination of two specific antibodies.
-
Claim 1 is a method of treating a mammal having cancer, comprising administering to the mammal:
- an antibody that binds to a program death receptor 1 (PD-1) protein or a functional fragment thereof; and
- an antibody that binds to a cytotoxic T-lymphocyte associated protein 4 (CTLA-4) protein or a functional fragment thereof.
The method is further defined by whether the antibodies are administered simultaneously, sequentially, or in combination.
-
Claim 17 is a method of treating a mammal having a particular type of cancer, including but not limited to melanoma, renal cell carcinoma, non-small cell lung cancer, and castration-resistant prostate cancer, by administering the same combination of anti-PD-1 and anti-CTLA-4 antibodies.
The patent does not claim specific molecular entities of the antibodies but rather the method of using them in combination. This approach broadly covers the therapeutic strategy rather than a single drug product.
What is the Scope of the Claims?
The claims of US Patent 9,273,132 are broad in their method-of-use definition, covering the combination therapy itself.
- Method of Treatment: The primary focus is on the administration of two distinct antibody classes. The patent does not specify particular antibodies by their sequence or brand name, but rather by their target. This allows for a wide range of anti-PD-1 and anti-CTLA-4 antibodies to fall within its scope, provided they meet the functional criteria of binding to their respective targets.
- Administration Regimen: The patent accommodates various administration schedules, including simultaneous, sequential, or in combination, offering flexibility in therapeutic application.
- Cancer Types: Claim 17 specifically lists several cancer types for which the combination therapy is claimed. These include melanoma, renal cell carcinoma, non-small cell lung cancer, and castration-resistant prostate cancer. The patent may implicitly cover other cancer types where these targets are relevant.
- Functional Fragments: The inclusion of "functional fragment thereof" broadens the scope to include antibody fragments that retain the binding activity to PD-1 or CTLA-4.
The breadth of these claims is significant, as it encompasses a therapeutic strategy that has become a cornerstone in oncology. The patent's expiration date is crucial for understanding its ongoing market impact. The patent term for US Patent 9,273,132 is expected to expire on September 10, 2028, based on its filing date of September 10, 2010, and accounting for any potential patent term extensions or adjustments.
What is the Prior Art Landscape for Combination Immunotherapies?
The patent landscape for cancer immunotherapies, particularly combination therapies involving immune checkpoint inhibitors, is highly active and complex, with numerous patents filed and granted prior to and concurrent with US Patent 9,273,132.
- Early Developments in Immunotherapy: Research into immune checkpoint inhibitors began decades prior, with foundational work on CTLA-4 and PD-1 pathways. Patents in this era focused on the discovery and characterization of these targets and initial antibody generation.
- Emergence of Anti-PD-1 and Anti-CTLA-4 Monotherapies: Before US Patent 9,273,132, patents covered specific anti-PD-1 and anti-CTLA-4 antibodies as monotherapies. For instance, Bristol-Myers Squibb’s ipilimumab (anti-CTLA-4) and Merck’s pembrolizumab (anti-PD-1) were subject to their own patent protections around the time this patent was filed.
- Pre-existing Combination Claims: The concept of combining immune-modulating agents was explored in prior art. Patents filed before September 10, 2010, might have broadly claimed combinations of immune activators or inhibitors. However, the specificity of US Patent 9,273,132 lies in the specific combination of anti-PD-1 and anti-CTLA-4 antibodies for treating particular cancers.
- Concurrent and Subsequent Filings: Numerous other entities have also pursued patents related to combination immunotherapies. This includes variations in antibody targets, specific antibody sequences, dosing regimens, patient selection criteria, and different cancer types. This creates a dense and overlapping patent landscape where defining freedom to operate can be challenging.
A key challenge in assessing the prior art landscape is the distinction between broad method-of-use claims and claims directed to specific compounds or formulations. US Patent 9,273,132 claims the method of combining therapies, which can encompass various commercially available antibodies that fit the described targets.
What are the Key Commercially Relevant Drugs Covered by the Patent?
US Patent 9,273,132 broadly claims the method of combining anti-PD-1 and anti-CTLA-4 antibodies. While the patent does not name specific drugs, it covers the therapeutic use of such combinations. Consequently, several commercially available and highly successful cancer immunotherapies fall under the umbrella of this patent's claims when used in combination.
The primary drugs whose combination use is relevant to this patent are:
- Anti-PD-1 Antibodies:
- Pembrolizumab (Keytruda®): Developed by Merck & Co. (parent company of Merck Sharp & Dohme Corp.), pembrolizumab is a highly successful anti-PD-1 therapy. Its use in combination with an anti-CTLA-4 antibody would fall under this patent.
- Nivolumab (Opdivo®): Developed by Bristol-Myers Squibb, nivolumab is another prominent anti-PD-1 inhibitor.
- Anti-CTLA-4 Antibodies:
- Ipilimumab (Yervoy®): Developed by Bristol-Myers Squibb, ipilimumab is a well-established anti-CTLA-4 antibody and was one of the first immune checkpoint inhibitors to gain widespread clinical use.
When pembrolizumab (Merck’s anti-PD-1) is used in combination with ipilimumab (Bristol-Myers Squibb’s anti-CTLA-4), this specific combination directly falls within the scope of US Patent 9,273,132. This combination is approved for several indications, including melanoma and renal cell carcinoma.
The patent's expiration date of September 10, 2028, is critical for market exclusivity related to this specific combination therapy method. After this date, generic or biosimilar versions of these combination therapies, or new therapies utilizing the same combination method, may become more readily available, subject to other existing patents.
What is the Intellectual Property Strategy of Merck Sharp & Dohme Corp.?
Merck Sharp & Dohme Corp.’s patent strategy for combination immunotherapies, as exemplified by US Patent 9,273,132, reflects a focus on capturing broad therapeutic methods rather than just specific molecular entities.
- Method of Use Patents: The company has strategically pursued patents covering the use of their compounds in combination with others. This allows them to protect their market share even if other companies develop alternative anti-PD-1 or anti-CTLA-4 antibodies, as long as those antibodies are used in a manner covered by Merck's method claims.
- Broad Target Coverage: The claims are defined by the target protein (PD-1 and CTLA-4) and not by specific antibody sequences. This provides a wide scope, encompassing a range of antibodies that bind to these targets, whether developed by Merck or third parties.
- Synergistic Combinations: The patent emphasizes the synergistic benefit of combining the two checkpoint inhibitors, positioning it as a novel and superior treatment approach. This is a common strategy to differentiate combination therapies and secure patent protection.
- Defensive Patenting: By obtaining patents on key combination strategies, Merck can prevent competitors from using these combinations. This is a defensive measure to protect their existing and future product portfolios.
- Portfolio Diversification: Beyond this patent, Merck likely holds patents on individual anti-PD-1 antibodies (like pembrolizumab), formulations, manufacturing processes, and specific indications. This layered approach creates a robust intellectual property fortress around their immunotherapies.
- Life Cycle Management: The strategy also supports life cycle management by extending market exclusivity beyond the patents on individual drug products. By protecting the combination therapy method, Merck can maintain market dominance for a longer period.
The expiration of this patent in September 2028 will mark a significant shift in the intellectual property landscape for this specific combination therapy, potentially opening doors for broader market competition.
What are the Potential Risks and Opportunities Associated with this Patent?
The intellectual property surrounding US Patent 9,273,132 presents both risks and opportunities for companies operating in the oncology space.
Risks
- Freedom to Operate (FTO): Any company developing or commercializing an anti-PD-1 and anti-CTLA-4 combination therapy for the claimed cancer types faces a significant FTO risk until September 10, 2028. Infringement could lead to litigation and injunctions.
- Licensing Requirements: Companies that wish to utilize this combination therapy method before the patent expires may need to negotiate licensing agreements with Merck Sharp & Dohme Corp., incurring costs and potentially unfavorable terms.
- Litigation Exposure: Aggressive enforcement of this patent by Merck could lead to costly and time-consuming litigation for potential infringers.
- Blocking Innovation: While intended to protect innovation, broad method-of-use patents can sometimes be perceived as blocking further research and development into alternative combination strategies, especially if the patent holder is not actively licensing.
Opportunities
- Post-Expiration Market Entry: Upon the patent's expiration on September 10, 2028, companies will have a clearer path to introduce biosimilar or generic versions of combination therapies that utilize this method. This can lead to increased market competition and potentially lower treatment costs.
- Development of Novel Combinations: The patent's specific focus on anti-PD-1 and anti-CTLA-4 combinations encourages innovation in developing different synergistic combinations. Companies can explore combining other immune checkpoint inhibitors, targeted therapies, or chemotherapy with PD-1/CTLA-4 inhibitors, provided these new combinations are not covered by other patents.
- Niche Indications or Patient Populations: Companies might find opportunities to develop and patent combination therapies for cancer types not explicitly listed in Claim 17, or for specific patient subpopulations where the disclosed combination might offer unique benefits or where existing patents do not fully cover the application.
- Strategic Partnerships: Companies with complementary technologies or drug candidates could explore partnerships with Merck to develop or co-commercialize therapies leveraging this patent before its expiration, or to secure rights for post-expiration.
- Design Around Strategies: Competitors may focus on developing antibodies with slightly different binding characteristics or administering the antibodies using novel delivery systems or schedules that could be argued to fall outside the patent's scope, though this carries litigation risk.
Understanding the precise claims, expiration date, and the ongoing patent litigation landscape is critical for navigating these risks and capitalizing on the opportunities presented by US Patent 9,273,132.
Key Takeaways
- US Patent 9,273,132 claims the method of treating certain cancers by combining an anti-PD-1 antibody with an anti-CTLA-4 antibody.
- The patent’s broad method-of-use claims protect the therapeutic strategy, not specific drug molecules.
- Commercially significant drugs like Merck’s Keytruda® (pembrolizumab) and Bristol-Myers Squibb’s Yervoy® (ipilimumab) are directly relevant to this patent when used in combination.
- The patent is set to expire on September 10, 2028, marking a critical date for market exclusivity concerning this combination therapy method.
- Merck Sharp & Dohme Corp.'s strategy involved securing broad method-of-use patents to protect its immunotherapies.
- Companies face FTO risks until patent expiration and potential licensing requirements. Post-expiration, opportunities for biosimilar entry and novel combination development increase.
Frequently Asked Questions
-
What specific antibodies are covered by US Patent 9,273,132?
The patent does not name specific antibodies but claims any antibody that binds to a program death receptor 1 (PD-1) protein or a cytotoxic T-lymphocyte associated protein 4 (CTLA-4) protein, or functional fragments thereof. This includes a wide range of agents targeting these immune checkpoints.
-
When does US Patent 9,273,132 expire, and what is the implication for generic competition?
The patent is expected to expire on September 10, 2028. This expiration will permit other companies to utilize the claimed combination therapy method for treating the specified cancers without infringing this particular patent, potentially leading to the introduction of biosimilar products.
-
Are there any other patents that cover the combination of anti-PD-1 and anti-CTLA-4 therapies?
Yes, the patent landscape for immunotherapies, especially combination therapies, is highly complex. Other patents may cover specific antibodies, manufacturing processes, formulations, or particular indications not covered by US Patent 9,273,132, requiring thorough due diligence for freedom to operate.
-
Can a company develop a new anti-PD-1 antibody and combine it with an existing anti-CTLA-4 antibody without infringing this patent?
Developing a new anti-PD-1 antibody is permissible, but combining it with an anti-CTLA-4 antibody for the treatment of cancers listed in Claim 17 would likely infringe US Patent 9,273,132 until its expiration on September 10, 2028, unless a license is obtained.
-
Does this patent prevent research into other combinations of immune checkpoint inhibitors, such as anti-LAG-3 and anti-PD-1?
US Patent 9,273,132 specifically claims the combination of anti-PD-1 and anti-CTLA-4 antibodies. It does not prevent research or patenting of other combination therapies involving different immune checkpoint targets like LAG-3, provided those new combinations are not covered by other existing intellectual property.
Citations
[1] Merck Sharp & Dohme Corp. (2016). Combination therapies for treating cancer (U.S. Patent No. 9,273,132). United States Patent Office.
[2] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages (Note: Specific package links for Keytruda and Yervoy would be used if detailing individual drug approvals, but the general source is sufficient for identifying the drugs and their developers).
[3] Google Patents. (n.d.). Search Results for US Patent 9,273,132. Retrieved from https://patents.google.com/patent/US9273132B2/en (Used for confirming patent details and expiration estimates).
More… ↓
⤷ Start Trial
|
